Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Modulation of Immune Activation by Aspirin

ClinicalTrials.gov ID: NCT02155985

Public ClinicalTrials.gov record NCT02155985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 22, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Since people started taking HIV medications, illness from AIDS has decreased, but other serious diseases like heart disease, cancer, and kidney, and liver disease have increased. HIV causes inflammation (irritation) inside the body that cannot be felt but can be measured by blood. Inflammation can lead to diseases that have become some of the leading causes of death in people with HIV. HIV therapy can partially lower levels of inflammation measured in blood, however, levels of inflammation in people who have HIV may remain high compared with people not infected with HIV. Aspirin is a drug that is commonly used for pain relief but is also approved by the Food and Drug Administration (FDA) for preventing heart attacks and stroke in those who are at increased risk for heart attack and stroke. Aspirin also is used (but is not approved by the FDA) to decrease the risk of some cancers in people who are at increased risk. Aspirin is thought to decrease risk of heart attack and stroke because it blocks the activation of platelets and prevents blood clots from clogging narrowed blood vessels, a disease called atherosclerosis. It is unknown how aspirin might decrease the chance of developing cancer in some people at higher risk, but aspirin has been shown to modulate (or change) the immune system. In HIV-infected people who have been taking antiretroviral therapy and have an undetectable HIV viral load it was recently shown that low-dose aspirin 81 mg (baby aspirin), given for one week, lowers platelet activation and reduces blood markers of inflammation which may improve the function of the immune system. The purpose of this study was to evaluate whether aspirin improves inflammation and immune activation when compared to a placebo (inactive medication like a dummy pill) and to determine if 12 weeks of aspirin 300 mg and aspirin 100 mg is safe for HIV-infected persons on antiretroviral therapy. Additionally, it studied whether a higher dose and longer duration of aspirin provides further anti-inflammatory and immune-modulating benefit. This was done using blood and urine tests that measure inflammation and also with a test that uses ultrasound to measure the flow of blood in your arm, called flow-mediated vasodilation (FMD) of the brachial artery (BART). This is a painless test that bounces sound waves off of a blood vessel in your arm.

Study identification

NCT ID
NCT02155985
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
121 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2014
Primary completion
May 31, 2015
Completion
Jun 30, 2015
Last update posted
Jun 11, 2017

2014 – 2015

United States locations

U.S. sites
15
U.S. states
8
U.S. cities
13
Facility City State ZIP Site status
601 University of California, Los Angeles CARE Center CRS Los Angeles California 90035
701 University of California, San Diego AntiViral Research Center CRS San Diego California 92103
Ucsf Aids Crs (801) San Francisco California 94110
Harbor-UCLA Med. Ctr. CRS (603) Torrance California 90502
University of Colorado Hospital CRS (6101) Aurora Colorado 80045
2701 Northwestern University CRS Chicago Illinois 60611
Rush Univ. Med. Ctr. ACTG CRS (2702) Chicago Illinois 60612
Massachusetts General Hospital ACTG CRS (101) Boston Massachusetts 02114
Brigham and Women's Hosp. ACTG CRS (107) Boston Massachusetts 02115
3201 Chapel Hill CRS Chapel Hill North Carolina 27516
Greensboro CRS (3203) Greensboro North Carolina 27401
Univ. of Cincinnati CRS (2401) Cincinnati Ohio 45267
Case CRS (2501) Cleveland Ohio 44106
3652 Vanderbilt Therapeutics (VT) CRS Nashville Tennessee 37204
Houston AIDS Research Team CRS (31473) Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02155985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 11, 2017 · Synced Sep 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02155985 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →